Second-line treatments for the management of advanced renal cell carcinoma: Systematic review and meta-analysis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 27-39

  Larkin, James ^a   Paine, Abby ^b   Tumur, Indra ^c   Cappelleri, Joseph C ^d   Healey, Paul J ^e   Foley, Grace ^c   Mitchell, Stephen ^b   Kroes, Michel ^a   Chen, Connie ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e PFIZER INC   (United States)

Author keywords

Disease free survival; Meta analysis; Renal cell carcinoma; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB;

ADVANCED CANCER; BAYESIAN LEARNING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

EID: 84871602797     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.758713     Document Type: Review

References (48)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90 (Pubitemid 41770167)
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92 (Pubitemid 46359643)
3. American Cancer Statistics. 2011
4. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352(9141):1691-6 (Pubitemid 28526138)
5. Porta C, Zimatore M, Imarisio I, et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution phase II study. Cancer 2004;100(10):2132-8 (Pubitemid 38580331)
6. DeVita VT, Hellman S, Rosenberg SA. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer principles and practice of oncology. Lippincott Williams & Wilkins; Philadelphia, PA; 2008
7. Atkins MB, Regan M, McDermott D, et al. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18 II):6342s-6s (Pubitemid 39287489)
8. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338(18):1272-8 (Pubitemid 28216581)
9. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110(11):2468-77 (Pubitemid 350174932)
10. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011;16(Suppl 2):45-50
11. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(Suppl 2):14-22
12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Kidney Cancer. Version 1. 2013. NCCN.org
13. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58(3):398-406
14. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
15. Hutson TE, Escudier B, Esteban E, et al. editors. Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: phase 3 results from the INTORSECT trial. ESMO; Vienna: 2012
16. Motzer R, Noscov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;30(Suppl):abstract 4501
17. Mills EJ, Bansback N, Ghement I, et al. Multiple treatment comparison metaanalyses: a step forward into complexity. Clin Epidemiol 2011;3:193-202
18. Porta C. How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shift. Eur Urol 2012;62(6):1020-1
19. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14(4):417-28
20. Altman DG. Practical statistics for medical research. Chapman & Hall; Boca Raton: 1991
21. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment- comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14(4):429-37
22. Spiegelhalter D, Thomas AA, Best N, Lunn D. WinBUGS user manual: version 1.4. MRC Biostatistics Unit; Cambridge: 2003
23. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
25. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
26. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org
27. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
28. Negrier S, Jager E, Porta C, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2010;27(3):899-906
29. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34 (Pubitemid 36910021)
30. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4068-75
31. Mills EJ, Rachlis B, O'Regan C, et al. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34
32. Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12(10):1491-7
33. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
34. Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48(3):333-9
35. Bracarda S, Hutson TE, Porta C, et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer 2012;24(9):1475-80
36. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
37. Lebwohl D, Kay A, Berg W, et al. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009;15(5):386-94
38. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101(23):1642-9
39. Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011;29(Suppl):abstract 4503
40. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14(22):7272-83
41. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011;11(2):113-26
42. Casciano R, Malangone E, Sherman S, et al. An indirect comparison of everloimus and sorafenib therapy in sunitinib-refractory mRCC patients. ASCO Annual Meeting; 4-8 June 2010; Chicago, IL; 2010
43. McCann L, Amit O, Pandite L, Amado RG. An indirect comparison analysis of pazopanib versus opther agents in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15 Suppl):e15128
44. Thompson Coon JS, Liu Z, Hoyle M, et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101(2):238-43
45. Knox JJ, Kay AC, Schiff E, et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15s Suppl):abstract TPS232
46. NICE technology appraisal guidance 215. Pazopanib for the first-line treatment of advanced renal cell carcinoma; 2011.
47. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454-63 (Pubitemid 41079774)
48. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40 (Pubitemid 29368255)